Barclays PLC Increases Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Barclays PLC boosted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 74.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 177,077 shares of the company’s stock after buying an additional 75,624 shares during the period. Barclays PLC owned approximately 0.21% of Atea Pharmaceuticals worth $593,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in Atea Pharmaceuticals during the 3rd quarter valued at approximately $36,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Atea Pharmaceuticals during the third quarter worth $37,000. China Universal Asset Management Co. Ltd. lifted its position in Atea Pharmaceuticals by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company’s stock valued at $54,000 after purchasing an additional 6,343 shares during the period. Zacks Investment Management purchased a new stake in Atea Pharmaceuticals in the third quarter valued at $80,000. Finally, SG Americas Securities LLC grew its position in Atea Pharmaceuticals by 117.9% during the 3rd quarter. SG Americas Securities LLC now owns 30,612 shares of the company’s stock worth $103,000 after purchasing an additional 16,561 shares during the period. Institutional investors and hedge funds own 86.67% of the company’s stock.

Insider Activity

In related news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Stock Performance

NASDAQ AVIR opened at $3.35 on Thursday. The firm has a market capitalization of $282.95 million, a P/E ratio of -1.62 and a beta of 0.20. The stock has a 50-day simple moving average of $3.27 and a two-hundred day simple moving average of $3.47. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.13. During the same period in the previous year, the firm earned ($0.40) EPS. As a group, analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.